TONIX Pharmaceuticals, Inc. Company Profile
TONIX Pharmaceuticals is developing new therapies for challenging disorders of the central nervous system (CNS). The Company targets conditions characterized by significant unmet medical need, inadequate existing treatment options, and high dissatisfaction among both patients and physicians. TONIX re-engineers known pharmaceutical agents to design drugs with optimal safety, efficacy and predictability. Its most advanced product candidates, TNX-102 for FM and TNX-105 for post-traumatic stress disorder (PTSD), are novel dosage oral formulations of cyclobenzaprine, the active ingredient in two U.S. FDA-approved muscle relaxants. To learn more about the Company and its pipeline of treatments for CNS conditions, please visit www.tonixpharma.com.
News Articles
Tonix Pharmaceuticals: Revolutionizing Fibromyalgia Treatment
By Capital Traders Group:I recently wrote an article regarding Jazz Pharmaceutical (JAZZ) and its wonder drug, Xyrem. In short, Jazz dominates the market for narcolepsy treatment because Xyrem (sodium...
Tonix: A Small Biotech With The Potentially Huge Key To The Fibromyalgia Puzzle
By Jason Napodano: By Jason Napodano, CFA The purpose of this article is to introduce investors to Tonix Pharmaceuticals (TNXP.OB) and the company's very low dose sublingual formulation of cycloben...
Tonix Readies For Pivotal Fibromyalgia Program
By Jason Napodano: In February 2013, Tonix Pharmaceuticals (TNXP.OB) management met face-to-face with the U.S. FDA to discuss the design of the clinical program for TNX-102SL, the company's low-dose s...
Tonix Pharmaceuticals Completes Private Placement
NEW YORK, Dec. 5, 2012 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (OTCQB:TNXP) ("TONIX" or the "Company"), a specialty pharmaceutical company developing novel treatments for challenging...
Tonix Pharmaceuticals to Present at Fifth Annual LD Micro Conference
NEW YORK, Dec. 5, 2012 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (OTCQB:TNXP) ("TONIX" or the "Company"), a specialty pharmaceutical company developing novel treatments for challenging...
Tonix completes private placement of convertible debentures and warrants
Tonix Pharmaceuticals to Hold Annual Shareholders' Meeting on April 19, 2013
NEW YORK, NY--(Marketwired - April 11, 2013) - Tonix Pharmaceuticals Holding Corp. (OTCQB: TNXP) ("TONIX" or "the Company"), a specialty pharmaceutical company developing novel treatments for challen...
Drugs and Medications
None
PubMed Articles
None
Clinical Trials
None
Companies
Tonix Pharmaceuticals Holding Corp.
TONIX Pharmaceuticals is developing new therapies for challenging disorders of the central nervous system. The Company targets conditions characterized by significant unmet medica...
TONIX Pharmaceuticals is developing new therapies for challenging disorders of the central nervous system (CNS). The Company targets conditions characterized by significant unmet...
TONIX Pharmaceuticals is developing new treatments for challenging disorders of the central nervous system. The Companyâs most advanced program targets fibromyalgia syndrome...
More Information about "TONIX Pharmaceuticals, Inc." on BioPortfolio
We have published hundreds of TONIX Pharmaceuticals, Inc. news stories on BioPortfolio along with dozens of TONIX Pharmaceuticals, Inc. Clinical Trials and PubMed Articles about TONIX Pharmaceuticals, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of TONIX Pharmaceuticals, Inc. Companies in our database. You can also find out about relevant TONIX Pharmaceuticals, Inc. Drugs and Medications on this site too.
